LabCorp(R) Advances Leadership Position in Drug Metabolism Testing With Expanded Services for Physicians Prescribing and Dosing Drugs

New Tool - Signature Genetics(TM) Drug Response Interpretation Service - Helps Physicians Make Better Drug Treatment Decisions BURLINGTON, N.C., May 3, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH), a national leader in

Laboratory Corporation of America(R) Holdings Announces 2006 First Quarter Results

Revenue Growth of 9.9% Drives Operating Cash Flow of $178.6 Million BURLINGTON, N.C., April 25, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced results for the first quarter ended March 31, 2006.

LabCorp To Present at the Lehman Brothers Global Healthcare Conference

Mar 08, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer,

LabCorp(R) Exclusively Licenses Yale Technology for New Early Stage Ovarian Cancer Blood Test

BURLINGTON, N.C., Feb. 23 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that it has entered into an exclusive license agreement with Yale University to commercialize the university's new blood testing technology for epithelial

Laboratory Corporation of America(R) Holdings Announces 2005 Fourth Quarter and Full Year Results

Strong Operating Cash Flow of $161 Million in the Fourth Quarter Helps Drive Record Annual Operating Cash Flow of $574 Million Feb 16, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced results for the quarter

LabCorp(R) Now Offering UGT1A1 Pharmacogenetic Test for Dosing Colorectal Cancer Therapy

Rights to Test for UGT1A1 Mutations Associated with Serious Adverse Reaction to Irinotecan Hydrochloride Sublicensed from Mayo Foundation BURLINGTON, N.C., Feb. 13 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced the availability of a

LabCorp To Present At The UBS Global Healthcare Services Conference

BURLINGTON, N.C., Feb. 10 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, are

LabCorp(R) Licenses the Signature Genetics(TM) Pharmacogenetic Interpretation and Reporting Service

Proprietary Service Helps Physicians Use CYP450 Information to Customize Medications for Optimal Patient Treatment BURLINGTON, N.C., Jan. 23 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that it has licensed a drug response

Dr. Leroy E. Hood and LabCorp(R) Establish Collaborative Relationship

BURLINGTON, N.C., Jan. 9 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that it has entered into a strategic consulting relationship with world renowned molecular biologist Leroy E. Hood, M.D., Ph.D. The collaboration will combine Dr.

LabCorp To Present at the JPMorgan Healthcare Conference

BURLINGTON, N.C., Jan. 9 /PRNewswire-FirstCall/ -- Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) today announced that Bradford T. Smith, Executive Vice President, Corporate Affairs, and William (Brad) Hayes, Executive Vice President and Chief Financial Officer, are scheduled